Scleroderma Diagnostics and Therapeutics

PUBLISHED: May 20, 2024

PAGES: 194 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Scleroderma Diagnostics and Therapeutics Market to Reach $2.8 Billion by 2030

The global market for Scleroderma Diagnostics and Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 4.1% over the period 2023-2030. Localized Scleroderma Diagnostics and Therapeutics, one of the segments analyzed in the report, is expected to record 4.5% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Systemic Scleroderma Diagnostics and Therapeutics segment is estimated at 3.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $627 Million, While China is Forecast to Grow at 3.8% CAGR

The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$627 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$486.3 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 3.5% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -

Actelion Pharmaceuticals Ltd.
Bayer AG
Boehringer Ingelheim International GmbH
Corbus Pharmaceuticals Holdings, Inc.
Cumberland Pharmaceuticals, Inc.
Cytori Therapeutics, Inc.
Gilead Sciences, Inc.
Pfizer, Inc.
Sanofi SA

Product Code: MCP16767

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Scleroderma Diagnostics and Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Immunosuppressive Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Endothelin receptor antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 10: World Scleroderma Diagnostics and Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Localized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 18: World Historic Review for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: World 16-Year Perspective for Systemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
JAPAN
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
CHINA
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: China Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: China Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
EUROPE
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
FRANCE
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 54: France Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 55: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 57: France Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 58: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
GERMANY
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 61: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 64: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 67: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 70: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 73: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 76: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 78: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 79: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 81: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 82: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 84: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 85: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 87: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 88: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 89: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 90: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 91: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 92: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 93: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 94: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030